20 completed, 1 unknown, 1 withdrawn. 22 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 20, Unknown 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Chronic Hepatitis C Infection: new trials by email Literature Review of Chronic Hepatitis C Infection trials Research Report on Chronic Hepatitis C Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Triple Combination DAAs for Treating HCV GT1b Subjects SOF+DCV+SMV - Chronic Hepatitis C Infection | Phase 2 | Withdrawn | Humanity and Health Research Centre | 2016-12-01 | 2017-05-12 | |
| A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C Infection | Phase 2 / Phase 3 | Completed | AbbVie | 64 | 2015-10-28 | 2021-10-05 |
| Switching Regimen in Treating Cirrhotic HCV GT1b Subjects PR4 + LDV/SOF + ASV 4 wk, PR4 + LDV/SOF + SMV 4 wk, PR4 + LDV/SOF + ASV 6 wk - Chronic Hepatitis C Infection | Phase 2 | Completed | Humanity and Health Research Centre | 138 | 2015-05-15 | 2025-03-26 |
| A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection ombitasvir/paritaprevir/ritonavir and dasabuvir, Sofosbuvir, Ribavirin - Chronic Hepatitis C Infection | Phase 2 | Completed | AbbVie | 29 | 2015-02-03 | 2017-12-20 |
| DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) Ledipasvir/Sofosbuvir, Sofosbuvir and Daclatasvir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir - Chronic Hepatitis C Infection, HBV Coinfection | Phase 2 / Phase 3 | Completed | Humanity and Health Research Centre | 23 | 2015-02-01 | 2021-09-01 |
| SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients Sofosbuvir, Daclatasvir - Chronic Hepatitis C Infection | Phase 2 / Phase 3 | Completed | Humanity and Health Research Centre | 106 | 2015-01-01 | 2018-03-19 |
| Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects LDV/SOF+ASV, SOF+DCV+SMV, SOF+DCV+ASV - Chronic Hepatitis C Infection | Phase 2 | Completed | Humanity and Health Research Centre | 18 | 2015-01-01 | 2016-03-01 |
| Clinical Investigation of Erlotinib as an HCV Entry Inhibitor 1- Erlotinib, placebo - Chronic Hepatitis C Infection, HCV Genotype 1b | Phase 1 / Phase 2 | Unknown | University Hospital, Strasbourg, France | 12 | 2013-05-01 | 2014-06-17 |
| An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV) - Chronic Hepatitis C Infection, Chronic Hepatitis C | Phase 2 | Completed | AbbVie | 38 | 2013-04-01 | 2018-05-30 |
| A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir, ribavirin - Chronic Hepatitis C Infection | Phase 2 | Completed | AbbVie | 129 | 2013-02-25 | 2017-11-07 |
| A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection ABT-450/ritonavir, ABT-267 - Chronic Hepatitis C Infection | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 110 | 2012-07-01 | 2018-05-30 |
| Herpes Simplex Type 1 Suppression in Hepatitis C Valacyclovir, Placebo - Chronic Hepatitis C Infection | Phase 2 | Completed | VA Office of Research and Development | 19 | 2012-04-01 | 2016-09-21 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects ABT-267, ABT-450, ABT-333 - Chronic Hepatitis C Infection | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 12 | 2012-02-01 | 2018-07-02 |
| A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin - Chronic Hepatitis C Infection, Genotype 1 | Phase 1 / Phase 2 | Completed | HanAll BioPharma Co., Ltd. | 30 | 2011-06-23 | 2025-04-22 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection ABT-450, ABT-333, ribavirin - Chronic Hepatitis C Infection, Hepatitis C | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 50 | 2011-02-01 | 2015-01-08 |
| Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3 SOF, RBV, PEG - Chronic Hepatitis C Infection | Phase 2 | Completed | Gilead Sciences | 292 | 2010-12-01 | 2014-11-17 |
| A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C GS-9190, GS-9256, Pegasys® - Chronic Hepatitis C Infection | Phase 2 | Completed | Gilead Sciences | 324 | 2010-10-01 | 2014-01-28 |
| A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) ABT-450, ABT-072, Ribavirin - Hepatitis C, HCV | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 11 | 2010-10-01 | 2015-01-08 |
| Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis Fuzheng Huayu, Placebo - Chronic Hepatitis C Infection | Phase 2 | Completed | Tarek Hassanein | 118 | 2010-08-01 | 2021-05-19 |
| Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients pegylated interferon and ribavirin, TG4040 + SOC - Chronic Hepatitis C Infection | Phase 2 | Completed | Transgene | 140 | 2010-05-01 | 2013-08-13 |
Showing 20 of 22. Sign in to see all of them.
Hepatitis C (13) · Hepatitis C, Chronic (3) · Fibrosis (1) · Hemophilia A (1) · Hepatitis (1) · Hepatitis, Chronic (1)
Digestive System Diseases (15) · Liver Diseases (15) · Blood-Borne Infections (14) · Communicable Diseases (14) · Flaviviridae Infections (14) · Hepatitis (14) · Hepatitis, Viral, Human (14) · Infections (14) · RNA Virus Infections (14) · Virus Diseases (14) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Chronic Disease (4) · Disease Attributes (4) · Hepatitis, Chronic (3)
Ribavirin (14) · paritaprevir (9) · dasabuvir (7) · ombitasvir (6) · Ritonavir (5) · Sofosbuvir (5) · peginterferon alfa-2a (5) · ledipasvir, sofosbuvir drug combination (4) · Viekira Pak (3) · daclatasvir (3) · ledipasvir (3) · ABT-072 (2) · Simeprevir (2) · GS-9256 (1) · GS-9669 (1)
AbbVie (prior sponsor, Abbott) (5) · Humanity and Health Research Centre (5) · AbbVie (4) · Gilead Sciences (2) · HanAll BioPharma Co., Ltd. (1) · Merck Sharp & Dohme LLC (1) · Tarek Hassanein (1) · Transgene (1) · University Hospital, Strasbourg, France (1) · VA Office of Research and Development (1)
United States (9) · China (4) · Germany (3) · Belgium (2) · France (2) · Puerto Rico (2) · Spain (2) · Austria (1) · Canada (1) · Czechia (1) · Hong Kong (1) · Italy (1) · New Zealand (1) · Poland (1) · United Kingdom (1)
Daniel Cohen, MD (2) · Andrew L Campbell, MD (1) · Bittoo Kanwar (1) · Dan Cohen, MD (1) · Daniel Cohen (1) · Dr Catherine Mutter, MD (1) · Dr Samira Fafi-Kremer, Pharma D, PhD (1) · Eric Cohen, MD (1) · George KK Lau, MD (1) · George Lau (1)
PMID 23281974, PMID 23281975, PMID 23439262, PMID 23439365, PMID 24262278, PMID 24657484, PMID 25386767, PMID 25451053, PMID 25644279, PMID 25839406, PMID 26596948, PMID 27917405, PMID 28842997, PMID 32451952
2015 (1)